Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial

Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial

Abstract Background Acute respiratory distress syndrome (ARDS) results in significant hypoxia, and ARDS is the central pathology of COVID-19. Inhaled prostacyclin has been proposed as a therapy for ARDS, but data regarding its role in this syndrome are unavailable. Therefore, we investigated whether...

Full description

Bibliographic Details
Main Authors: Helene A. Haeberle, Stefanie Calov, Peter Martus, Lina Maria Serna-Higuita, Michael Koeppen, Almuth Goll, Alice Bernard, Alexander Zarbock, Melanie Meersch, Raphael Weiss, Martin Mehrländer, Gernot Marx, Christian Putensen, Tamam Bakchoul, Harry Magunia, Bernhard Nieswandt, Valbona Mirakaj, Peter Rosenberger
Format: Article
Language:English
Published: BMC 2023-02-01
Series:Respiratory Research
Subjects:
ARDS
Prostacyclin
COVID-19
Inflammation
Therapy
Online Access:https://doi.org/10.1186/s12931-023-02346-0

Internet

https://doi.org/10.1186/s12931-023-02346-0

Similar Items